Biotech itself may be a relatively risky proposition, but there are ways of reducing risk. The buildings used by the sector, for example, could be a safer bet.

The Noé Group partners Zvi Noé, Raphael Noe and David Bloom feature in Financial Times discussing life sciences real estate, Capreon investments from Eindhoven to Madrid and Goldacre's portfolio including Kao Data.

Read more here: